IVD & Diagnostics

How to lock down antibody clones, manage lot-to-lot bridging studies, and maintain immunoassay performance across manufacturing campaigns — covering recombinant vs hybridoma strategies, critical quality attribute monitoring, bridging study design, and regulatory expectations under FDA QMSR, ISO 13485, and EU IVDR.

How to source biological specimen raw materials — human serum, plasma, urine, CSF, and tissue-derived matrices — for IVD calibrator and control manufacturing, including donor qualification, viral testing, traceability, TSE/BSE compliance, lot-to-lot consistency, and regulatory requirements under FDA 21 CFR 610, EU IVDR, and ISO 13485.

How to establish metrological traceability of calibrators and controls for in vitro diagnostic kits — covering ISO 17511:2020 calibration hierarchy models, JCTLM reference materials, WHO international standards, certified reference materials, commutability assessment, measurement uncertainty budgeting, value assignment protocols, and regulatory expectations under FDA, EU IVDR, and ISO 13485.

How to qualify and manage enzyme suppliers for PCR and RT-qPCR in vitro diagnostic kits — covering Taq polymerase, hot-start variants, reverse transcriptase, lot-to-lot testing protocols, incoming acceptance specifications, stability requirements, change notification, and regulatory expectations under FDA QMSR, ISO 13485, and EU IVDR.

How to prepare an IVD CDMO technology transfer readiness package — documentation requirements, process validation ownership, quality agreement structure, analytical method transfer, regulatory filing strategy, and risk mitigation under FDA 21 CFR 820/QMSR, ISO 13485, and EU IVDR.

How to design, manufacture, and stabilize lyophilized (freeze-dried) reagents for in vitro diagnostic kits — covering lyophilization process optimization, formulation excipients, lyo-bead and lyo-cake formats, fill-finish humidity control, residual moisture specification, accelerated and real-time stability studies, ICH Q1A application, container closure integrity, and regulatory expectations for FDA, EU IVDR, and ISO 13485.

How to select, qualify, and control magnetic beads, polystyrene latex particles, and gold nanoparticles as critical raw materials for IVD assays — covering chemiluminescent immunoassay (CLIA) magnetic beads, immunoturbidimetric latex particles, lateral flow gold colloid, particle characterization specifications, lot-to-lot bridging, conjugation chemistry, supplier qualification, and regulatory expectations under FDA QMSR, ISO 13485, and EU IVDR.

How to select materials and suppliers for microfluidic cartridges and diagnostic tapes in IVD devices — covering COC, COP, PMMA, PC, and PP polymer properties, Solventum/3M diagnostic tape families (9792R, 9793R, 9795R, 9964, 9965, 9972A), injection molding and hot embossing for microfluidic features, bonding techniques (laser welding, thermal bonding, adhesive lamination, ultrasonic welding), extractable and leachable testing, biocompatibility, channel design for manufacturing, supplier qualification under ISO 13485, and process validation for IVD cartridge production.

How to select nitrocellulose membranes for lateral flow assay IVD products — pore size, capillary flow rate, protein binding capacity, backing type, thickness, striping parameters, lot-to-lot qualification, and regulatory considerations under FDA and EU IVDR.

How to qualify and manage oligonucleotide, primer, and probe suppliers for PCR, RT-qPCR, and molecular diagnostic IVD kits — covering synthesis quality grades, purity specifications, lot release testing, contamination control, lot-to-lot bridging, change notification, and regulatory requirements under FDA QMSR, ISO 13485, and EU IVDR.

Roche entered a definitive agreement to acquire PathAI on May 7, 2026, for $750M upfront plus up to $300M in milestone payments, adding the AISight digital pathology platform and AI-based biomarker algorithms to its diagnostics division. Covers PathAI's technology for cancer screening and companion diagnostic development, the $1.1B+ AI pathology market, regulatory considerations for AI/ML-based SaMD, and implications for precision oncology and IVD regulatory strategy.

How to qualify sample pads, conjugate pads, and absorbent pads for lateral flow assay IVD products — material selection, pretreatment chemistry, lot-to-lot consistency testing, incoming material specifications, and regulatory requirements under FDA QMSR and ISO 13485.

CareDx agreed to acquire Naveris for up to $260M on April 28, 2026, marking its strategic expansion from transplant diagnostics into HPV-driven cancer surveillance. Covers NavDx liquid biopsy technology, TTMV DNA biomarker science, deal structure ($160M upfront + $100M milestones), CareDx's divestiture of Lab Products, and the $4.5B molecular residual disease monitoring market.

In-depth analysis of Danaher's $9.9 billion acquisition of Masimo, the largest medtech deal of 2026. Covers deal structure, strategic rationale, regulatory and antitrust considerations, competitive landscape impact on patient monitoring, and what it means for device manufacturers, hospitals, and investors.

A practical survival guide for IVD manufacturers facing the May 26, 2026 IVDR Class C transition deadline. Covers who must apply to a Notified Body, the September 2026 agreement deadline, conditions for extended market access through 2028, common pitfalls, and a step-by-step action plan.

Operational guide to the invalid-result workflow for home-use and self-test IVDs — covering invalid rate targets, lay-user error coding, repeat-test instructions, IFU comprehension, customer support scripts, specimen collection errors, adverse event handling, and postmarket trending.

Practical guide to change control for NGS bioinformatics pipelines in IVD devices — covering variant caller updates, reference database changes, threshold modifications, wet-lab/software interface validation, IEC 62304 documentation, revalidation triggers, and postmarket records.

Operational guide to converting an RUO-labeled assay or reagent into a cleared or approved IVD — covering marketing claims cleanup, distributor scripts, customer notices, historical data triage, validation bridge strategy, complaint transition, sales training, and evidence firewall construction.

Dedicated CLIA waiver playbook for IVD manufacturers — covering waived, moderate, and high complexity categories, CW submission content, flex studies, lay-user studies, the Dual 510(k) + CLIA Waiver pathway, review timelines, common deficiencies, and real-world examples.

Regulatory, commercial, and privacy risk guide for direct-to-consumer (DTC) genetic testing companies — covering FDA oversight of DTC IVDs, wellness vs. medical claims boundaries, analytical and clinical validity requirements, risk report authorization, GINA and state privacy laws, FTC advertising substantiation, 23andMe bankruptcy data precedent, and practical guidance on claims that change regulatory status.